ClinicalTrials.gg

Program

elritercept

Also written as “Elritercept” and “TAK-226”.

Its studies are mostly in Myelodysplastic Syndromes · Primary Myelofibrosis, led by Takeda.

Furthest: phase 3, since Jul 5, 20246 company-led studies, 6 open or runningNext primary completion: Feb 28, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda66 open or runningphase 3since Jul 5, 2024Jun 3, 2020Feb 28, 2028phase 2 · NCT05037760

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 3, 2020First study: phase 2 study in Myelodysplastic SyndromesFirst studyNCT04419649 · 210 planned · United States, Australia, Czechia and more
  2. Aug 23, 2021Phase 2 study in Primary MyelofibrosisNCT05037760 · 135 planned · Australia, Brazil, France and more
  3. Jul 5, 2024Phase 3 study in Myelodysplastic SyndromesNCT06499285 · 225 planned · United States, Australia, Brazil and more
  4. Dec 22, 2025Phase 2 study in Myelodysplastic SyndromesNCT07319845 · 42 planned · Japan
  5. Feb 6, 2026Phase 3 study in Myelodysplastic SyndromesNCT07422480 · 300 planned · United States, Argentina, Australia and more
  6. May 29, 2026Phase 3 study in Primary MyelofibrosisNCT07623161 · 324 planned · United States, Argentina, Australia and more
  7. Oct 23, 2026Primary completion moved from 2028-05-01 to 2028-09-15Date moved laterphase 3 · +5 months · NCT06499285

Ahead

  1. Feb 28, 2028Primary completion: phase 2 study in Primary MyelofibrosisNCT05037760
  2. Jun 26, 2028Primary completion: phase 2 study in Myelodysplastic SyndromesNCT07319845
  3. Sep 15, 2028Primary completion: phase 3 study in Myelodysplastic SyndromesNCT06499285
  4. Apr 30, 2029Primary completion: phase 3 study in Myelodysplastic SyndromesNCT07422480

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07623161Primary Myelofibrosis · United States, Argentina, Australia and more3RecruitingDec 7, 2029324
NCT07422480Myelodysplastic Syndromes · United States, Argentina, Australia and more3RecruitingApr 30, 2029300
NCT07319845Myelodysplastic Syndromes · Japan2RecruitingJun 26, 202842
NCT06499285Myelodysplastic Syndromes · United States, Australia, Brazil and more3RecruitingSep 15, 2028225
NCT05037760Primary Myelofibrosis · Australia, Brazil, France and more2RecruitingFeb 28, 2028135
NCT04419649Myelodysplastic Syndromes · United States, Australia, Czechia and more2RecruitingOct 30, 2029210

How it is read

Names in the registry

  • “Elritercept”, 5 entries
  • “TAK-226”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.